Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS
Price as at 1 Oct 2026, 01:53 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Sarepta Therapeutics, Inc. trades at $18.22. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Two Sigma, TWO SIGMA INVESTMENTS, LP$82.64M · 0.1% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$76.87M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$39.64M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$21.45M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$20.15M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in SRPT
We hold 14 disclosed trades in SRPT by members of Congress and executive-branch officials. The latest 5:
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 14 Apr 2025 · disclosed 6 May 2025
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 4 Jun 2024 · disclosed 22 Aug 2026
- Daniel Goldman · HouseSell · $15,001 - $50,000 · traded 10 Apr 2023 · disclosed 19 May 2023
- Daniel Goldman · HouseBuy · $15,001 - $50,000 · traded 6 Mar 2023 · disclosed 17 Apr 2023
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own SRPT?
7 of the institutions we track reported a position in SRPT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its SRPT data?
Fundamentals for SRPT come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:53 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for SRPT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.